Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy
Public ClinicalTrials.gov record NCT00566722. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label study was conducted in a patient population of moderate to severe chronic plaque psoriasis patients, which is an approved patient population for adalimumab.
Study identification
- NCT ID
- NCT00566722
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 152 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Mar 31, 2009
- Completion
- Mar 31, 2009
- Last update posted
- Apr 11, 2011
2008 – 2009
United States locations
- U.S. sites
- 18
- U.S. states
- 14
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Total Skin and Beauty Dermatology Centers | Birmingham | Alabama | 35205 | — |
| Dermatology Research of Arkansas | Little Rock | Arkansas | 72205 | — |
| Therapeutics Clinical Research | San Diego | California | 92123 | — |
| Florida Academic Dermatology Centers | Miami | Florida | 33136 | — |
| Peachtree Dermatology Associates | Atlanta | Georgia | 30327 | — |
| Dawes Fretzin Clinical Research Group | Indianapolis | Indiana | 46256 | — |
| ORA Clinical Research and Development | Andover | Massachusetts | 01810 | — |
| New York University School of Medicine | New York | New York | 10016 | — |
| Mount Sinai School of Medicine | New York | New York | 10029 | — |
| Montifiore Medical Center | The Bronx | New York | 10467 | — |
| Paddington Testing Co. | Philadelphia | Pennsylvania | 19103 | — |
| Clinical Partners | Johnston | Rhode Island | 02919 | — |
| Radiant Research | Greer | South Carolina | 29651 | — |
| Dermatology Treatment & Research Center, PA Research | Dallas | Texas | 75230 | — |
| Baylor Research Institute | Dallas | Texas | 75246 | — |
| Center for Clinical Studies | Houston | Texas | 77058 | — |
| Virginia Clinical Research, Inc. | Norfolk | Virginia | 23507 | — |
| Dermatology Associates | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00566722, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2011 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00566722 live on ClinicalTrials.gov.